Published in Women's Health Weekly, July 3rd, 2003
Patients were eligible to enter the phase II metastatic breast cancer trial if they had shown ongoing growth of their tumor even after receiving either Taxol and/or Taxotere therapy. In this refractory or resistant population, ABI-007 was administered...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly